Johan Engdahl

The majority of our projects are clinical trials, many of them with hard clinical endpoints. One of the landmark studies on atrial fibrillation screening, STROKESTOP (NCT01593553), was performed by our group. The biomarker-enhanced STROKESTOP II (NCT02743416) will report the primary endpoint during 2024. A randomised clinical trial on AF detection post stroke (AF SPICE, NCT05134454) is recruiting from 30 stroke units in Sweden and will report its primary endpoint in 2028. Further projects include developement and implementation of smartphone PPG heart rhythm diagnosis (SMARTBEATS, NCT04300270), digital, siteless and risk prediction model-enhanced atrial fibrillation screening in high-risk groups (CONSIDERING-AF, NCT05838781), the relation between excessive supraventricular activity and atrial fibrillation (ESA AF, NCT04593498) and a longitudinal study on progression of atrial fibrllation in the young (PRAY, NCT05080712).